中文
| Catalogue |
| Recommend Products |
Company News
- AMSBIO: iPS-Cell Based Cell Therapies for Genetic Skin Disease 9/2/2022
- AMSBIO Expand Range of Laminin Isoforms 8/16/2022
- AMSBIO: Optimized Lentiviral Vectors to Speed Up Your Research 7/28/2022
- AMSBIO: Pre-clinical Screening Technology Increases Cancer Test Numbers 7/18/2022
- AMSBIO: Comprehensive Toolkit for Investigating Oxidative Stress 7/13/2022
- AMSBIO: Assay Kits, Biomarkers and Antibodies for Investigating Oxidative Stress 6/21/2022
- AMSBIO: Tools to Advance Cellular Metabolism Research 6/9/2022
- AMSBIO: Polyspecific Antibodies for Cancer Research 5/30/2022
- AMSBIO: Aptamers for Cancer Diagnosis and Therapy 5/19/2022
- AMSBIO: Clinical-grade Recombinant Proteins for Cell Therapy 5/5/2022
- AMSBIO: Isolation of High Purity Exosomes 4/12/2022
- AMSBIO: Crucial Tools for COVID-19 Omicron Research 3/22/2022
- AMSBIO LLC: One-step ELISA Experiments 3/15/2022
- Obesity and Mitochondria Transfer: is Heparan Sulfate the Way In? 3/1/2022
- AMSBIO: Expanded Range of Nucleic Acid Extraction Kits for Pathogens Detection 2/10/2022
- AMSBIO Expands EU Operations 1/27/2022
- AMSBIO: Latest Tools for COVID-19 Omicron Variant Research 1/10/2022
- AMSBIO: Services to Accelerate Genome Editing Research 12/17/2021
- AMSBIO: High Quality Products for Cultured Meat Research 12/9/2021
- AMSBIO: Custom Biofluid & Tissue Procurement Service 12/1/2021